Cytosorbents (CTSO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$7.5 million.
- Cytosorbents' Enterprise Value fell 1593.85% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 1593.85%. This contributed to the annual value of -$8.3 million for FY2024, which is 4140.6% up from last year.
- As of Q3 2025, Cytosorbents' Enterprise Value stood at -$7.5 million, which was down 1593.85% from -$10.2 million recorded in Q2 2025.
- In the past 5 years, Cytosorbents' Enterprise Value registered a high of -$6.5 million during Q3 2024, and its lowest value of -$68.5 million during Q1 2021.
- In the last 5 years, Cytosorbents' Enterprise Value had a median value of -$14.1 million in 2023 and averaged -$25.3 million.
- As far as peak fluctuations go, Cytosorbents' Enterprise Value tumbled by 15945.75% in 2021, and later soared by 6305.51% in 2022.
- Cytosorbents' Enterprise Value (Quarter) stood at -$52.1 million in 2021, then surged by 57.53% to -$22.1 million in 2022, then skyrocketed by 36.19% to -$14.1 million in 2023, then surged by 41.41% to -$8.3 million in 2024, then rose by 8.99% to -$7.5 million in 2025.
- Its Enterprise Value was -$7.5 million in Q3 2025, compared to -$10.2 million in Q2 2025 and -$11.6 million in Q1 2025.